Time without transfusion reliance (TWiTR): Integrating survival quality into myelofibrosis treatment strategies based on the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Researchers evaluated time without transfusion reliance—a method that integrates transfusion dependence and survival quality—to three phase 3 trials of treatment with momelotinib in patients with myelofibrosis. The time without transfusion reliance analysis demonstrated that patients treated with momelotinib versus comparators spent more time free from transfusions and anemia events.